New SELECT analysis finds heart benefit appears before major weight loss

An analysis of the SELECT cardiovascular outcomes trial found that reductions in major heart events among people taking Wegovy showed up early, before participants had lost a clinically meaningful amount of weight ^[1]. The finding was presented as new evidence that semaglutide's cardiovascular benefit may not come only from shedding pounds.

SELECT is the large trial that established Wegovy's heart-protection indication. In August 2023, Novo Nordisk reported that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity who had established cardiovascular disease ^[1]. Full results were presented at the American Heart Association Scientific Sessions in November 2023 and published simultaneously in the New England Journal of Medicine ^[1]. Based largely on this trial, the FDA approved Wegovy in March 2024 to reduce the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight ^[1].

The new analysis, described in a company announcement dated May 13, 2025, and titled "In New SELECT Trial Analysis, Early Reduction in Cardiovascular Events Was Observed with Wegovy, Before Clinically Meaningful Changes in Body Weight," reported that the drop in cardiovascular events appeared before patients had lost enough weight to be considered clinically meaningful ^[1]. This timing detail is the core of the finding: if heart benefit shows up before major weight loss occurs, that points to the drug affecting the cardiovascular system through some pathway other than pounds lost, such as effects on inflammation, blood vessels, or other biological processes ^[1]. The sources reviewed here do not specify the exact percentage of weight loss at the point when cardiovascular benefit was first detected, nor do they detail what alternative biological mechanisms were proposed; that level of detail is not yet known from the available material.

This early-benefit finding sits alongside other cardiovascular data Novo Nordisk has released for Wegovy. In August 2025, the company reported a real-world study finding that Wegovy cut the risk of heart attack, stroke, or death by 57% compared with tirzepatide in people with obesity and cardiovascular disease ^[1]. That is a separate, later analysis and involves a different comparison — against another GLP-1 drug rather than placebo — so it should not be read as confirming the same mechanism finding from the SELECT sub-analysis ^[1].

Why it matters for patients

For patients taking Wegovy for heart risk reduction, this analysis suggests the cardiovascular protection may not be simply a side effect of losing weight. That distinction matters because it could mean the drug's value for heart health does not depend entirely on how much weight a person loses. Some patients lose weight more slowly or plateau at lower amounts than others, and this finding raises the possibility that heart benefits could still be occurring even for those patients. However, the sources here do not provide effect sizes broken down by how much weight was lost, so patients cannot use this finding to predict their own individual heart-risk reduction based on their weight-loss progress ^[1].

It is also worth noting that Wegovy's FDA-approved cardiovascular indication is specifically for adults who already have established cardiovascular disease along with obesity or overweight ^[1]. This analysis does not change or expand who the drug is approved for; it adds evidence about how the existing benefit may work.

What happens next

The sources reviewed do not describe any planned follow-up studies specifically designed to isolate the mechanism behind this early cardiovascular benefit, so further mechanistic research timelines are not yet known. Novo Nordisk has continued to release additional SELECT-related and other Wegovy trial analyses in the time since, including data on liver health benefits in MASH patients not solely tied to weight loss, reported in November 2025 ^[1], suggesting the company continues to explore weight-independent effects of semaglutide across different conditions.